for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Laboratorios Farmaceuticos ROVI SA

ROVI.MC

Latest Trade

39.00EUR

Change

0.50(+1.30%)

Volume

62,370

Today's Range

38.40

 - 

39.60

52 Week Range

20.00

 - 

42.50

As of on the Mercado Continuo Espana ∙ Minimum 15 minute delay

Pricing

Previous Close
38.50
Open
39.00
Volume
62,370
3M AVG Volume
1.59
Today's High
39.60
Today's Low
38.40
52 Week High
42.50
52 Week Low
20.00
Shares Out (MIL)
55.39
Market Cap (MIL)
2,186.69
Forward P/E
40.23
Dividend (Yield %)
0.45

Latest Developments

More

Rovi Releases Results Of Phase III Clinical Trial Of Its Drug In Schizophrenic Patients

Rovi Confirms Its Long Term Indicative Guidance For 2023

Rovi 9-Month EBITDA Up 47% YoY

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Laboratorios Farmaceuticos ROVI SA

Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spain-based company principally engaged in the pharmaceutical industry. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which distributes medicines under such brands as Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi and Absorcol, among others; and Over The Counter (OTC), which comprises the Perspirex, Enerzona, Dentimelo and ColdPack brands. The Company owns such fully consolidated subsidiaries as Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL and Bertex Pharma GmbH, among others.

Industry

Biotechnology & Drugs

Contact Info

C/ Julian Camarillo, 35

MADRID, MAD

28037

Spain

+34.913.756230

https://www.rovi.es/

Executive Leadership

Juan Lopez-Belmonte Lopez

Chairman of the Board

Juan Lopez-Belmonte Encina

Chief Executive Officer, Executive Director

Javier Lopez-Belmonte Encina

Second Vice Chairman of the Board, Chief Financial Officer, Executive Director

Ivan Jorge Lopez-Belmonte Encina

First Vice Chairman of the Board, Executive Director of Corporate Development

Beatriz Avila Alcalde

Sales Manager Line B

Key Stats

1.89 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

0.3K

2018

0.3K

2019

0.4K

2020(E)

0.4K
EPS (EUR)

2017

0.350

2018

0.350

2019

0.720

2020(E)

0.930
Price To Earnings (TTM)
38.91
Price To Sales (TTM)
5.30
Price To Book (MRQ)
5.85
Price To Cash Flow (TTM)
30.92
Total Debt To Equity (MRQ)
20.27
LT Debt To Equity (MRQ)
18.65
Return on Investment (TTM)
13.73
Return on Equity (TTM)
10.93

Latest News

Latest News

Moderna signs deal with Spain's Rovi to supply potential COVID-19 vaccine outside U.S.

Moderna Inc said on Thursday it has signed an agreement with Spain's Laboratorios Farmacéuticos Rovi SA to scale up the manufacturing and production of its potential COVID-19 vaccine to supply markets outside the United States.

Moderna signs contract for filling potential COVID-19 vaccine vials by Spain's Rovi

Moderna Inc said on Thursday it has signed an agreement with Spain's Laboratorios Farmacéuticos Rovi SA to provide vial filling and packaging capacity for its potential COVID-19 vaccine to supply markets outside of the Unites States.

BRIEF-Rovi Announces Collaboration With Moderna For Manufacturing Covid-19 Vaccine Candidate

* ANNOUNCED COLLABORATION WITH MODERNA FOR OUTSIDE UNITED STATES FILL-FINISH MANUFACTURING OF MODERNA’S COVID-19 VACCINE CANDIDATE

BRIEF-Rovi Q1 Net Profit Up At 13.9 Mln Euros YoY, Sees Main Negative Impact On Group's Sales In Q2

* Q1 NET PROFIT 13.9 MILLION EUROS VERSUS 6.9 MILLION EUROS YEAR AGO

BRIEF-Rovi Signs Co-Operation Deal For Clinical Trial To Study Efficacy And Safety Of Bemiparin For Pneumonia Caused By COVID-19

* SIGNS CO-OPERATION AGREEMENT FOR CLINICAL TRIAL TO STUDY EFFICACY AND SAFETY OF BEMIPARIN IN PATIENTS HOSPITALISED WITH PNEUMONIA CAUSED BY COVID-19 Source text: https://bit.ly/34AcHZk Further company coverage: (Gdansk Newsroom)

BRIEF-Rovi Expects Main Negative Impact Of COVID-19 On Group Sales In Q2 2020

* BELIEVES THAT THERE WILL BE A RISE IN ITS LOW MOLECULAR-WEIGHT HEPARINS SALES IN HOSPITALS DURING THE PERIOD OF THE HEALTH CRISIS

BRIEF-Rovi FY Net Profit Up At 39.3 Mln Euros YoY

* FY NET PROFIT 39.3 MILLION EUROS VERSUS 17.9 MILLION EUROS YEAR AGO

BRIEF-Rovi Signs Distribution Agreement With Sandoz

* REACHES AGREEMENT WITH SANDOZ, A UNIT OF NOVARTIS, FOR DISTRIBUTION AND MARKETING OF ITS ENOXAPARIN BIOSIMILAR

BRIEF-ROVI FY Net Profit Down At 17.2 Mln Euros

LABORATORIOS FARMACEUTICOS ROVI SA (ROVI) :

BRIEF-Rovi Gets 45 Million Euro Loan From European Investment Bank

* GETS 45 MILLION EURO LOAN FROM EUROPEAN INVESTMENT BANK Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up